Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research

Table 4

This table summarizes the different drugs, details of clinical trials completed in AIS, route (i.v.: intravenous; s.c.: subcutaneous), phases, n/a: not available, number of patients enrolled, and clinical trial number.

Summary of trials for neuroinflammation, excitotoxicity, and oxidative stress drugs
Drug	Dose	Time window	Phase	Number of patients	Clinical trial number	Citation
SA4503	Oral treatment of 1 mg/d and 3 mg/d for a period of 28 days	48 to 72 hours	2	60	NCT00639249	[16]
Caffeinol + hypothermia	Infusion of caffeinol (9 mg/kg caffeine + 0.4 g/kg ethanol) over 2 hours	4 hours	1/2	30	NCT00299416	[17]
Edaravone	12.5 mg/37.5 mg/62.5 mg one dose every 12 hours, for period of 14 days	24 hours	2	400	NCT01929096	[18]
RP-1127	3 mg/day i.v. 3 boluses followed by infusion for 72 hours	≤10 hours	2	10	NCT01268683	[19]
RP-1127	i.v. bolus followed by continuous infusion for 72 hours	4.5 hours	2	34	NCT01132703	[20]
Filgrastim	s.c. 15 μg/kg per day for 5 days	7 days	n/a	10	n/a	[21]
Filgrastim	3 i.v. doses (150, 300, or 450 μg/body/day, divided into 2 doses for 5 days)	24 hours and 7 days	1	18	n/a	[22]
AX200 (G-CSF)	4 i.v. doses, total cumulative doses of 30–180 μg/kg over the course of 3 days	<12 hours	2a	44	NCT00132470	[23]
AX200 (filgrastim)	135 µg/kg i.v. over 72 hours	9 hours	2	328	NCT00927836	[24]
Leucostim	10 mg/kg s.c. per day for 5 days	≤48 hours	2	20	NCT00901381	[25]
3K3A-APC	3K3A-APC at 6, 30, 90, 180, 360, 540, or 720 g/kg and 5 doses: 90, 180, 360, or 540 g/kg every 12 hours after safety of the first. g/kg every 12 hours after safety of the first	Measurements at 12 and 24 hours	1	64	NCT01660230	[26]
3K3A-APC	3K3A-APC at 120 ug/kg, 240 ug/kg, 360 ug/kg, or 540 ug/kg	Measurements at 12 hours for up to 5 doses	2	100	NCT02222714	Not yet published